These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG. Nikolaev A; Fiveash JB; Yang ES Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975 [TBL] [Abstract][Full Text] [Related]
3. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309 [TBL] [Abstract][Full Text] [Related]
4. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma. An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043 [TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. Gits HC; Anderson M; Stallard S; Pratt D; Zon B; Howell C; Kumar-Sinha C; Vats P; Kasaian K; Polan D; Matuszak M; Spratt DE; Leonard M; Qin T; Zhao L; Leach J; Chaney B; Escorza NY; Hendershot J; Jones B; Fuller C; Leary S; Bartels U; Bouffet E; Yock TI; Robertson P; Mody R; Venneti S; Chinnaiyan AM; Fouladi M; Gottardo NG; Koschmann C Acta Neuropathol Commun; 2018 Jul; 6(1):67. PubMed ID: 30049282 [TBL] [Abstract][Full Text] [Related]
6. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients. Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307 [TBL] [Abstract][Full Text] [Related]
13. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023 [TBL] [Abstract][Full Text] [Related]
14. Signal Transduction in Diffuse Intrinsic Pontine Glioma. Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874 [TBL] [Abstract][Full Text] [Related]
15. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162 [TBL] [Abstract][Full Text] [Related]
16. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401 [TBL] [Abstract][Full Text] [Related]
17. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503 [TBL] [Abstract][Full Text] [Related]
18. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions. van den Bent M; Saratsis AM; Geurts M; Franceschi E Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230 [TBL] [Abstract][Full Text] [Related]
19. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma. Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas. Lu VM; Daniels DJ Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]